Zubir Ahmed MP: speeches

Speeches

• 21 Apr 2026 · Wheelchair Provision: Independent Review Body · Hansard source

  More

  I totally agree with my hon. Friend. That is partly a reflection of the underfunding of aspects of the NHS over the past decade and a half. As she well knows, our party supports the NHS, and we have funded it with £26 billion of additional funding. That will clearly take time to filter through to the services that require the most. The Government are also driving forward improvements for disabled people through our wider reforms to health and social care. The recently published neighbourhood health framework aims to improve health and care outcomes, and reduce inequalities through more convenient, personalised and joined-up care. It includes a focus on improving the diagnosis and treatment of people with long-term conditions, so that they feel more in control of their care. In July 2025, the Government announced that we will develop a new plan for disability, setting out a clear vision to break down barriers to opportunity for disabled people. We are making more than £4.6 billion of additional funding available for adult social care in 2028-29 compared with 2025-26, to support the sector and make the improvements that we all crave. We have also established the better care fund, a framework for ICBs and local authorities to make joint plans and pool budgets to deliver better, joined-up holistic care. This financial year, ICBs and local authorities plan to spend £440 million on assistive technology and equipment such as wheelchairs. We also continue to invest in support for home adaptations to enable independent living, with £723 million confirmed for the disabled facilities grant this year. The disabled facilities grant budget across 2025-26 and 2026-27 is £150 million more than the total budget across the previous two years, representing an 11% increase that exceeds inflation. The independent commission into adult social care, chaired by Baroness Louise Casey, is building consensus on the medium and long-term reforms required to create a social care system that is fit for the future, with the phase 1 report due this year. I recognise the profound impact that delays in wheelchair provision are having on the quality of life of hon. Members’ constituents, and I am grateful to my hon. Friend the Member for Bexleyheath and Crayford for highlighting that today. He had a number of asks of me, to which I hope I have responded. I am cognisant of the work he has done and the personal attention he gives to these matters, and I offer him a meeting with Department officials in my office to go through them in greater detail. My officials will be in touch to arrange that. I hope that the work, reforms and modernisation I have set out address the questions he has raised. I assure hon. Members that we take this issue extremely seriously, and remain committed to improving the lives of disabled people up and down our country.

• 15 Apr 2026 · Draft Health and Social Care Act 2008 (Regulated Activities) (Amendment) Regulations 2026 · Hansard source

  More

  Thank you again for chairing the Committee, Mr Stringer. The shadow Minister is very knowledgeable about these matters. Like her, I have been an attending doctor at events, and I am very sensitive to the representations she made, as well those made by other colleagues over the last few weeks and months. Much of what she talked about relates to the definition of “quality”, but defining that is not for the Government but for experts, clinicians and regulatory bodies, which is why it is so important that we give the CQC the power to do this. I do not want small events and village fêtes to be overregulated; that is not the intention of this legislation. Nor do I want individual doctors, clinicians and other volunteers to be over-burdened with financial registration fees, and we will look into this with the CQC. Given the changes that have been made to the CQC governance architecture, I believe that it is absolutely the right body to do this work, which is basically an extension of what it already does in hospitals, care homes and GP surgeries up and down the land. The tragic events in Manchester highlighted the care gap, and this Government intend to ensure that it is closed for the benefit of our citizens attending events up and down the county. By amending the CQC’s regulation, event organisers and those attending events can be reassured that the medical cover provided is adequate and of a suitable quality. Regardless of the size and type of event, a basal level of quality must be assured.

• 11 Mar 2026 · Disability Equipment Provision · Hansard source

  More

  In the interest of time, I will not, but I think I know where the hon. Gentleman wants to go with this, with the NRS. I will be happy to write more fully—

• 24 Feb 2026 · People with Down’s Syndrome: Sport and Health · Hansard source

  More

  Every child with a disability should have the opportunity to reap the health and wellbeing benefits of being active. We are working across health, education and sports to break down barriers to physical activity, including for children with Down’s syndrome. That includes ensuring that they have access to inclusive, sensory-rich activities that they can enjoy with friends, families and carers.

• 12 Feb 2026 · Pharmacy First: Withholding Payments · Hansard source

  More

  It is a pleasure to take the traditional Department of Health and Social Care urgent question before recess—I would not miss it for the world. Since coming into office, we have reversed the decade of cuts to community pharmacy with the biggest uplift for the sector in years and frozen prescription charges to help our constituents with the cost of living, and women can now get the morning-after pill free of charge across the country. Earlier this week, I spoke to the National Pharmacy Association’s winter reception to pay tribute to its members for their work and to assure them that I have their back, as does the Minister for Care. The hon. Member for Hinckley and Bosworth (Dr Evans) raises the important issue of payments made via Pharmacy First. As he knows, pharmacy contractors receive a monthly fixed payment if they meet certain requirements. We agreed to reduce the claim window, in conjunction with Community Pharmacy England, as part of our deal for 2025-26 to introduce a new Pharmacy First fixed first payment of £500. That has supported a broader range of pharmacies and has meant that more pharmacies have become eligible for payments. We are in discussions with Community Pharmacy England to consider where improvements to the claiming process can be made, address concerns raised by contractors and aim for a more consistent approach to remuneration. We will also consult with Community Pharmacy England shortly on the contractual framework for next year. There are issues relating to contractors being suspended from providing Pharmacy First that are for separate consideration. When concerns are raised, NHS England can suspend individual contractors from providing the service pending a full investigation. There are a number of reasons why that might be necessary, but the measures are there, first and foremost, as the House will appreciate, to protect patient safety. I am a clinician, as is the hon. Member for Hinckley and Bosworth, and I am sure that he will agree that patient safety should be at the forefront of everything we do. Finally, funding for the core community pharmacy contractual framework has been increased to over £3 billion—the largest uplift of any part of the NHS in the last two years. As part of this year’s contractual framework, we have agreed to keep the current cost control mechanism linked to Pharmacy First that we inherited from the previous Government to ensure that the money is spent within that envelope. I thank the hon. Gentleman for his question.

• 9 Feb 2026 · Brain Tumour Survival Rates · Hansard source

  More

  I could not agree more with my hon. Friend, and that is why NIHR funding has been specifically allocated. One of the tests for a grant is the diversity of the population it will serve. We recognise the challenges presented by brain tumours. By publishing regular performance data at a more granular level and adding diagnosis in emergency settings to our basket of early diagnosis metrics, we are committed to moving the dial on these issues. For all patients diagnosed with rare cancers, we will prioritise access to specialist treatment and multidisciplinary teams to ensure that they benefit from the best of evidence-based care. We will work with charities to support rare cancer patients, and to ensure that they have access to the right information to manage their cancer care. We wish to be held accountable on these commitments and to drive forward progress for rare cancer patients, and we will therefore appoint a national clinical lead for rare cancers, who will provide independent arbitration. The actions I have listed make up just a small part of our plan. It will turn cancer, which is one of the country’s biggest killers, into a treatable chronic condition. We have developed our plans with patients, charities, families and clinicians, and have heard from many Members today. We are grateful for the continued campaigning on rare cancers and brain tumours.

• 21 Jan 2026 · Draft Medical Devices (Fees Amendment) Regulations 2026 · Hansard source

  More

  I am happy to write to the hon. Lady to give her a fuller answer. She knows that procurement in different parts of the NHS rightly reflects local clinical practices, although there are overarching national frameworks for buying such products. Innovation lends itself to the fact that, over time, patients will want to choose and move on to newer forms of devices that treat their conditions in line with the latest clinical evidence. I am very happy to write to her more extensively on obsolescence and her other questions. I would like to address some points made on the following topics: the impact on SMEs; the impact on market attractiveness more extensively; GMDN suitability and transparency; clarity on costs; and the evaluation of value for money. I also want to make some points regarding Northern Ireland. On SMEs, as the Opposition spokesperson highlighted, I recognise that new regulatory costs can be felt more sharply by smaller firms, and the MHRA has listened carefully. That is why the fee has been designed to spread costs more equitably across the sector, and the majority will pay only £300 per year. Following consultation feedback, charging is based on the number of GMDN level 2 categories that a manufacturer’s registered device falls into, rather than the much more granular level 5. That matters for SMEs because they are more likely to have closely related product variants that may attract multiple level 5 terms, but sit more generally within a single level 2 category. Under this approach, multiple products in one level 2 category are therefore charged once per year, reducing the need for repeat charges on minor product variations. The MHRA estimates that around 56% of manufacturers will pay a single unit fee of £300 a year, and SMEs are most likely to fall into that group, because they typically have a narrower product range than the larger companies. The MHRA is not offering waivers or special SME rates. The charge is designed to be proportionate, and any waiver would simply shift costs elsewhere. The intention is to keep the charge predictable and proportionate, and to phase it in. Finally, SMEs stand to benefit from a stronger PMS framework, leading to earlier identification of issues, fewer surprises and a more risk-proportionate and predictable regulatory approach that supports responsible innovation. I must make it clear that we are not asking for more money: we are simply changing the MHRA’s regulatory framework to put it on a more sustainable footing so that in the future it is less reliant on the taxpayer and, therefore, more pro-innovation, more pro-market and better able to have a healthier commercial relationship with new and established companies. On innovation and UK attractiveness, a robust PMS framework is not a brake on innovation—far from it. It helps to make the market more predictable and investable, as per my conversations over the last couple of weeks with major and smaller biotech industry firms. In developing this instrument, we have ensured that the Secretary of State must have regard to three considerations set out in the Medicines and Medical Devices Act 2021: safety, availability, and the attractiveness of the whole of the United Kingdom as a place to research, develop, manufacture and, crucially, supply medical devices. This fee supports safety by ensuring the MHRA has sustainable funding for strengthened PMS, so that risks can be identified and acted on sooner. It supports availability by underpinning a stable and predictable system of oversight that helps to maintain continued safe access to effective devices.

• 20 Jan 2026 · ADHD Diagnosis · Hansard source

  More

  I thank my hon. Friend for her very valid point. It is important to mention that we expect that the prevalence review will align with the review that the Department for Work and Pensions is carrying out on employability and other issues affecting disability. NHS England is working with ICBs that are trialling innovative ways of delivering ADHD services and is using this information to support systems to tackle ADHD waiting lists and provide support to address people’s needs. I understand that it is increasingly clear to patients and staff that the current highly specialist ADHD assessment model needs to evolve quickly. Moving to a more generalist service model could improve care and reduce waiting lists. That was one of the taskforce’s key recommendations.

• 17 Nov 2025 · Clive Treacey Safety Checklist · Hansard source

  More

  I thank my hon. Friend the Member for Lichfield (Dave Robertson) for securing this important debate. I recognise the efforts of Clive’s family, particularly Elaine and Michael who join us today in the Gallery. As my hon. Friend described in his wonderful speech, Clive Treacey was a caring, gentle and humorous man, who liked to paint and who enjoyed gardening and listening to music. As we have heard, Clive also had a learning disability and epilepsy, and sadly he died in 2017, at the age of just 47, following a seizure. His loss, I am sure, is still felt very deeply by his family and loved ones. I pay tribute to all the work that they have done by channelling the tragedy they have been through, and the work that they continue to do in advocating for change following Clive’s death. The independent review into Clive’s death highlighted that there were multiple system-wide failures in delivering his care and treatment that together placed him at a higher risk of sudden death. It was found that Clive experienced sub-optimal care and support throughout his life and death, and that he was not always placed in settings that could meet his needs, in terms of both epilepsy care and support for his disability. I am pleased that since Clive’s death, meaningful changes have been made. Following the publication of the independent review into his death in December 2021, organisations directly involved in Clive’s care developed high-level actions in response to its findings and there was an overwhelming commitment from all organisations involved to address the systemic issues raised in the report. NHS England midlands region set up a group that became known as the Clive Treacey conscience group and last year it published “Clive’s Way: A Conscience Manual”, outlining in detail the progress the midlands region is making in taking forward and implementing the learnings from the independent review. We know that around 30% of people with epilepsy have a learning disability and that the risk of sudden unexpected death in epilepsy is much higher for those with a learning disability, as my hon. Friend pointed out. The latest annual LeDeR—learning from lives and deaths—report found that epilepsy was one of the most common underlying causes of death for people with a learning disability between 2021 and 2023. That highlights how crucial it is that information and support for patients with epilepsy who have a learning disability are tailored to their individual needs. We welcome the development of the Clive Treacey safety checklist; it is an important part of Clive’s legacy. We encourage commissioners and service providers to use the checklist and its accompanying guidance as a key tool when designing services for their local populations and to ensure that the steps outlined in the checklist are followed whenever a patient experiences a significant change in their care. Since Clive’s death, a number of NHS regions have reviewed the way that they care for patients living with a learning disability and epilepsy—

• 28 Oct 2025 · World Stroke Day · Hansard source

  More

  It is a pleasure to serve under your chairmanship, Ms Vaz. I thank the hon. Member for Twickenham (Munira Wilson) for securing this timely debate and wish her mother well in her recovery. It is not easy to channel personal pain for the greater good, but the hon. Member has done so, along with my hon. Friends the Members for Stratford and Bow (Uma Kumaran) and for South West Norfolk (Terry Jermy). They can be assured that their articulation in this place of their personal experience will prevent strokes and lead to their faster treatment. Often, debates such as this can increase awareness and reduce the threshold at which people contact the NHS and the ambulance service for help. The hon. Member for Twickenham asked me to address a number of issues, and I will do so before I get into the bulk of my speech. One was about data capture. Although I am responding on behalf of the public health Minister, my hon. Friend the Member for West Lancashire (Ashley Dalton), I am the Minister responsible for digital health and data, so I can assure the hon. Member that the interconnectivity of data among primary care, secondary care and social care is important to me, both for ease of access for the patient and for learnings and auditing. She can be assured of my personal commitment that that is the way forward in the new iteration of a modern health service. The hon. Member also asked about physiotherapy and disability reduction. I can reassure her that, through the workforce plan and our upgrading of the digital architecture, we are working intensively to see how we can bring world-class physiotherapy to all and not just to some. Part of disability reduction is timely access to cutting-edge treatments, which no longer involves clot-busting; it now involves clot removal, in the form of thrombectomy. Thrombectomy services are planned to be totally universal in England by April 2026. I hope that answers some of the questions the hon. Member for Sleaford and North Hykeham (Dr Johnson) asked about those services.